Moving Toward Patient-Tailored Treatment in ALS and FTD: The Potential of Genomic Assessment as a Tool for Biological Discovery and Trial Recruitment.

Broce, Iris J; Castruita, Patricia A; Yokoyama, Jennifer S

Broce, Iris J; Castruita, Patricia A; Yokoyama, Jennifer S.

Afiliação

Broce IJ; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.
Castruita PA; Department of Family Medicine and Public Health, University of California, San Diego, San Diego, CA, United States.
Yokoyama JS; Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.

Front Neurosci ; 15: 639078, 2021.

Article em En | MEDLINE | ID: mdl-33732107

Palavras-chave

amyotrophic lateral sclerosis; clinical trials; frontotemporal dementia; genomics; precision medicine

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Neurosci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google